Form 8-K - Current report:
SEC Accession No. 0000950170-25-056736
Filing Date
2025-04-22
Accepted
2025-04-22 16:14:50
Documents
17
Period of Report
2025-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apvo-20250421.htm   iXBRL 8-K 57999
2 EX-5.1 apvo-ex5_1.htm EX-5.1 26483
3 EX-10.1 apvo-ex10_1.htm EX-10.1 168132
4 EX-10.2 apvo-ex10_2.htm EX-10.2 308481
5 EX-99.1 apvo-ex99_1.htm EX-99.1 18450
6 EX-99.2 apvo-ex99_2.htm EX-99.2 17967
7 GRAPHIC img57496738_0.jpg GRAPHIC 12962
  Complete submission text file 0000950170-25-056736.txt   831933

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apvo-20250421.xsd EX-101.SCH 26037
19 EXTRACTED XBRL INSTANCE DOCUMENT apvo-20250421_htm.xml XML 4925
Mailing Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121
Business Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 206-838-0500
Aptevo Therapeutics Inc. (Filer) CIK: 0001671584 (see all company filings)

EIN.: 811567056 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37746 | Film No.: 25857892
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)